Ceritinib as a long-term disease control: Clinical observation
https://doi.org/10.21518/ms2024-238
Abstract
ALK-positive non-small cell lung cancer is an excellent model demonstrating the success of precision medicine. A rare genetic disorder – a rearrangement of the anaplastic large cell lymphoma gene, occurring with a frequency of 5–7%, forms a certain clinical and morphological portrait of the patient. In ALK-positive non-small cell lung cancer, the brain is a frequent target for metastasis. But despite this negative prognosis factor, it is in this cohort of non-small cell lung cancer patients that the achievements of drug antitumor therapy are especially significant – the consistent use of ALK inhibitors of several generations allows to achieve a median overall survival of about 80 months. In the Russian Federation, 4 drugs have been approved for the treatment of ALK-positive non-small cell lung cancer. One of them is a second–generation ALK inhibitor – ceritinib is actively used both in the first line of therapy and after progression on crizotinib. In the ASCEND-4 registration study, the median time to progression on ceritinib was twice as long as on standard polychemotherapy. However, the initial daily dose of the drug 750 mg was associated with severe gastrointestinal and hepatotoxicity. Subsequently, the dose of the drug was reduced to 450 mg, which significantly improved the tolerability of treatment without reducing its effectiveness. The clinical case presented below demonstrates the possibility of modern targeted therapy to provide long-term disease control in metastatic ALK-positive nonsmall cell lung cancer.
About the Authors
E. V. Reutova
Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Elena V. Reutova - Cand. Sci. (Med.), Senior Researcher of Cancer Drug Therapy Department No. 3.
23, Kashirskoye Shosse, Moscow, 115478
K. K. Laktionov
Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Konstantin K. Laktionov - Dr. Sci. (Med.), Head of Cancer Drug Therapy Department No. 3, Blokhin National Medical Research Center of Oncology; Professor of the Department of Oncology and X-ray Therapy, General Medicine Faculty, Pirogov RNRMU.
23, Kashirskoye Shosse, Moscow, 115478; 1, Ostrovityanov St., Moscow, 117997
M. A. Ardzinba
Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Merab A. Ardzinba, Cand. Sci. (Med.), Researcher of the Cancer Drug Therapy Department No. 3.
23, Kashirskoye Shosse, Moscow, 115478
References
1. Demidova IA, Tsepenshchikova EO, Barinov AA, Gagarin IM, Savelov NA, Grinevich VN, Tyulyandin SA. Determination of rearrangements in ALK gene in selected Russian population of patients with non-small cell lung cancer. Malignant Tumours. 2013;(3):3–9. (In Russ.) https://doi.org/10.18027/2224-5057-2013-3-3-9.
2. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol. 2009;27(26):4232–4235. https://doi.org/10.1200/JCO.2009.23.6661.
3. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006. https://doi.org/10.1001/jama.2014.3741.
4. Laktionov KK, Artamonova EV, Breder VV, Gorbunova VA, Demidova IA, Dengina NV et al. Non-small cell lung cancer. Malignant Tumors. 2023;13(3s2-1):42–65. (In Russ.) https://doi.org/10.18027/2224-5057-2023-13-3s2-1-42-65.
5. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929. https://doi.org/10.1016/S0140-6736(17)30123-X.
6. Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–463. https://doi.org/10.1016/S1470-2045(15)00614-2.
7. Chow LQM, Barlesi F, Bertino EM, van den Bent MJ, Wakelee HA, Wen PY et al. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clin Cancer Res. 2022;28(12):2506–2516. https://doi.org/10.1158/1078-0432.CCR-21-1838.
8. Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G et al. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357–1367. https://doi.org/10.1016/j.jtho.2017.07.005.
9. Otoukesh S, Sanchez T, Mirshahidi S, Wallace D, Mirshahidi H. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective. Cancer Treat Res Commun. 2019;20:100149. https://doi.org/10.1016/j.ctarc.2019.100149.
10. Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol. 2016;34(24):2866–2873. https://doi.org/10.1200/JCO.2015.65.5936.
11. Li J, Knoll S, Bocharova I, Tang W, Signorovitch J. Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls. Curr Med Res Opin. 2019;35(1):105–111. https://doi.org/10.1080/03007995.2018.1541443.
12. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R et al. Molecular Mechanisms of Resistance to Firstand Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016;6(10):1118–1133. https://doi.org/10.1158/2159-8290.CD-16-0596.
13. Fukui T, Tachihara M, Nagano T, Kobayashi K. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. Cancers (Basel). 2022;14(5):1184. https://doi.org/10.3390/cancers14051184.
14. Hansen KH, Johansen JS, Urbanska EM, Meldgaard P, Hjorth-Hansen P, Kristiansen C et al. Clinical outcomes of ALK+ non-small cell lung cancer in Denmark. Acta Oncol. 2023;62(12):1775–1783. https://doi.org/10.1080/0284186X.2023.2263153.
15. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–1064. https://doi.org/10.1016/j.annonc.2020.04.478.
16. Lenderking WR, Lin H, Speck RM, Zhu Y, Huang H, Huang J et al. Patientreported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA). Future Oncol. 2019;15(24):2841–2855. https://doi.org/10.2217/fon-2019-0185.
17. Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354–366. https://doi.org/10.1016/S2213-2600(22)00437-4.
18. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10(2):232–236. https://doi.org/10.1097/JTO.0000000000000455.
Review
For citations:
Reutova EV, Laktionov KK, Ardzinba MA. Ceritinib as a long-term disease control: Clinical observation. Meditsinskiy sovet = Medical Council. 2024;(10):60-65. (In Russ.) https://doi.org/10.21518/ms2024-238
Views:
183
Email this article 